Evidence map›Paper›PMID 39591144›Full record

ArticleVaccines2024

STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.

Simon Woelfel, Daniel Junker, Irina Bergamin, Pamela Meyer-Herbon, Roman Stillhard, Nicole Graf, Georg Leinenkugel, Joel Dütschler, Marius König, Livia Kammerlander and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Simon WoelfelDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.ORCID 0000-0003-2528-0582
Daniel JunkerNMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Irina BergaminDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Pamela Meyer-HerbonDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Roman StillhardDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Nicole GrafClinical Trials Unit, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.ORCID 0000-0002-5527-5365
Georg LeinenkugelUniversity Center for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital of Basel, 4002 Basel, Switzerland.
Joel DütschlerDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Marius KönigDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Livia KammerlanderDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Rahel HäuptleDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Sarah ZwyssigDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Claudia KriegerDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Samuel TrunigerDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Seraina KollerDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Katline Metzger-PeterUniversity Center for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital of Basel, 4002 Basel, Switzerland.ORCID 0009-0000-3133-0887
Nicola FreiDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Star Sign Study Investigators
Werner C AlbrichDivision of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.ORCID 0000-0003-0607-7159
Matthias FriedrichTranslational Gastroenterology and Liver Unit, Nuffield Department of Medicine, University of Oxford, Oxford OX3 9DU, UK.
Christine BernsmeierUniversity Center for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital of Basel, 4002 Basel, Switzerland.
Jan Hendrik NiessUniversity Center for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital of Basel, 4002 Basel, Switzerland.ORCID 0000-0001-6902-5650
Wolfgang KorteCenter for Laboratory Medicine, 9001 St. Gallen, Switzerland.
Justus J BürgiCenter for Laboratory Medicine, 9001 St. Gallen, Switzerland.
Alex DulovicNMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Nicole Schneiderhan-MarraNMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.ORCID 0000-0001-6785-181X
David SemelaDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Stephan BrandDepartment of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.

Funding

Cantonal Hospital St. GallenHorizon Europe European Research Council 101003480-CORESMAState Ministry of Baden-Württemberg for Economic Affairs, Labor Tourism FKZ-3- 4332.62- NMI- 67 and FKZ 3-4332.62-NMI- 68University of Oxford
6 · The paper itself

Abstract

backgroundPatients with chronic liver disease (CLD) have impaired vaccine immunogenicity and an excess risk of severe COVID-19. While variant-adapted COVID-19 mRNA vaccines are recommended for vulnerable individuals, their efficacy in patients with CLD has not been studied.

methodsWe present the first evaluation of XBB.1.5 COVID-19 vaccine immunogenicity against the SARS-CoV-2 JN.1 variant in patients with CLD. Serum anti-receptor binding domain (RBD) IgG, neutralization, and saliva anti-RBD IgG and IgA against wild-type SARS-CoV-2 (WT) and the XBB.1.5, EG.5.1, BA.2.86, and JN.1 variants were quantified before and 2-4 weeks following a fourth dose of XBB.1.5 mRNA vaccines.

resultsVaccination boosted anti-RBD IgG and neutralization against all tested variants including JN.1 (each

conclusionXBB.1.5 vaccines protect CLD patients against recent SARS-CoV-2 variants, but developing vaccines with optimized mucosal immunogenicity is required to prevent SARS-CoV-2 transmission and recurrent seasonal COVID-19 outbreaks.

Indexed as

autoimmune hepatitisBA.2.86chronic liver diseaseCOVID-19EG.5.1IBDinflammatory bowel diseaseJN.1liver cirrhosisliver transplantationmRNA vaccinesmucosal immunogenicitySARS-CoV-2SARS-CoV-2 neutralizationXBB.1.5XBB.1.5 vaccines

Identifiers

PMID39591144
PMCPMC11598625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.